Journals / Turkish Journal of Pharmaceutical Sciences / 2021 / Cilt: 18 - Sayı: 4

QbD-based Formulation Optimization and Characterization of Polymeric Nanoparticles of Cinacalcet Hydrochloride with Improved Biopharmaceutical Attributes

Geliştirilmiş Biyofarmasötik Özelliklere Sahip Sinakalset Hidroklorürün Polimerik Nanopartiküllerinin QbD Tabanlı Formülasyon Optimizasyonu ve Karakterizasyonu

Pages
77–89
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The prepared polymeric nanoparticles formulation is an alternative delivery system for enhanced therapeutic efficacy and bioavailability potential of a model drug to manage long-term normocalcemia in patients with preliminary hyperparathyroidism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of the present work was to prepare QbD enabled optimization, and to improve the oral bioavailability of freeze–dried polymeric nanoparticles of cinacalcet hydrochloride manufactured by nanoprecipitation and ultrasonication methods using polymers PLGA, and poloxamer-188.
📊
Key Findings & Data:The optimized batch was stable as per the ICH stability guidelines for 6 months with no considerable alternation noticed in particle size, entrapment efficiency, and in vitro drug release.
💡
Conclusion & Impact:Conclusion: The prepared polymeric nanoparticles formulation is an alternative delivery system for enhanced therapeutic efficacy and bioavailability potential of a model drug to manage long-term normocalcemia in patients with preliminary hyperparathyroidism.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of the present work was to prepare QbD enabled optimization, and to improve the oral bioavailability of freeze–dried polymeric nanoparticles of cinacalcet hydrochloride manufactured by nanoprecipitation and ultrasonication methods using polymers PLGA, and poloxamer-188. Materials and Methods: The initial screening and optimization were carried out for the formulations by employing Taguchi and Box-Behnken Designs. The FT-IR and DSC revealed no interactions and had no incompatibility among the selected drug and polymers. The nanoparticles were characterized for % drug release, particle size analysis, zeta potential, PDI, SEM, TEM, P-XRD, TGA, DTA, in vitro, and in vivo drug release study. Results: In vitro drug release study showed sustained release of the drug from the optimized batch by diffusion mechanism. The optimized nanoparticle formulation was recognized by numerical and graphical methods using validation of the experimental model. The optimized batch was stable as per the ICH stability guidelines for 6 months with no considerable alternation noticed in particle size, entrapment efficiency, and in vitro drug release. The pharmacokinetic parameters of AUC and Cmax data for the optimized formulation increased 3- and 2.9-folds compared to the pure-drug suspension. Conclusion: The prepared polymeric nanoparticles formulation is an alternative delivery system for enhanced therapeutic efficacy and bioavailability potential of a model drug to manage long-term normocalcemia in patients with preliminary hyperparathyroidism.

Özet

Amaç: Mevcut çalışmanın amacı, QbD özellikli optimizasyon hazırlamak ve polimerler PLGA ve poloksamer-188 kullanılarak nano-prepikipitasyon ve ultrasonikasyon yöntemleri ile üretilen cinacalcet hidroklorürün dondurularak kurutulmuş polimerik nanopartiküllerinin oral biyoyararlanımını geliştirmekti. Gereç ve Yöntemler: Formülasyonlar için taguchi ve Box-Behnken Tasarımları kullanılarak ilk tarama ve optimizasyon gerçekleştirildi. FT-IR ve DSC hiçbir etkileşim ortaya koydu ve seçilen ilaç ve polimerler arasında uyumsuzluk yoktu. Nanopartiküller % ilaç salınımı, partikül boyutu analizi, zeta potansiyeli, PDI, SEM, TEM, P-XRD, TGA, DTA, in vitro ve in vivo ilaç salınım çalışması ile karakterize edildi. Bulgular: In vitro ilaç salınım çalışması, ilacın difüzyon mekanizması ile optimize edilmiş partiden sürekli olarak salındı. Optimize edilmiş nanopartikül formülasyonu, deneysel modelin doğrulanması kullanılarak sayısal ve grafiksel yöntemlerle tanındı. Optimize edilmiş parti, parçacık boyutu, tuzak verimliliği ve in vitro ilaç salınımında fark edilen önemli bir değişiklik olmadan 6 ay boyunca ICH stabilite yönergelerine göre kararlıydı. Optimize edilmiş formülasyon için AUC ve Cmax verilerinin farmakokinetik parametreleri, saf ilaç süspansiyonu ile karşılaştırıldığında 3 ve 2,9 kat arttı. Sonuç: Hazırlanan polimerik nanopartiküller formülasyonu, ön hiperparatiroidisi olan hastalarda uzun süreli normokalsemiyi yönetmek için model bir ilacın gelişmiş terapötik etkinliği ve biyoyararlanım potansiyeli için alternatif bir doğum sistemidir.

🔖

Cite This Article

GHOSE, D., PATRA, C. N., KUMAR, B. V. V. R., SWAIN, S., JENA, B. R., CHOUDHURY, P., SHREE, D. (2022). QbD-based Formulation Optimization and Characterization of Polymeric Nanoparticles of Cinacalcet Hydrochloride with Improved Biopharmaceutical Attributes. Turkish Journal of Pharmaceutical Sciences, Cilt: 18 - Sayı: 4, 77–89. https://ajindex.com/articles/613622

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Peer D, Karp JM, Hong S, Faro Khzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-760. Davis ME,Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7:771-782.
  2. Quintanar-Guerrero D, Allemann Fessi EH, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24:1113-1128.
  3. Bhanoji Rao ME, Swain S, Patra CN, Mund SP. Formulation design, optimization and characterization of eprosartanmesylate nanoparticles. Nanosci Nanotech-Asia. 2018;8:2130-2143. Kreuter J. Nanoparticles-a historical perspective. Int J Pharm. 2007;331:1- 10. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1-20.
  4. Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly-(epsiloncaprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm. 2005;293:261-270. Glen A. The impact of nanotechnology in drug delivery: global developments, Market Analysis Future Prospects, 2005. Last Accessed Date: 31.03.09. Available from: http://www.nanomarkets.com
  5. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardio toxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000;8:1029-1033.
  6. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci. 1998;87:1305-1307.
  7. Raghuvanshi RS, Katare YK, Lalwani K, Ali MM, Singh O, Panda AK. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int J Pharm. 2002;245:109-121.
  8. Kreutera J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood- brain barrier using surfactant-coated nano-particles. J Control Release. 1997;49:81-87.
  9. Allemann E, Gurny R, Christophe JL. Biodegradable nanoparticles- from sustained release formulations to improved site specific drug delivery. J Control Release. 1996;39:339. Moffitt M, Khougaz K, Eisenberg A, Micellization of ionic block copolymers. Acc Chem Res. 1996;29:95-102.
  10. Sushant SK, Yogesh M, Choudh